Title:Ultrasound Promoted Synthesis and Anticoagulant Activity of 2-Amino- 4H-chromen-4-ylphosphonates
Volume: 14
Issue: 3
Author(s): Sarva Santhisudha, Tellamekala Sreekanth, Sudileti Murali, Bathal V. Kumar, Meruva A. Devi and Cirandur S. Reddy
Affiliation:
Keywords:
2-Amino-4h-chromen-4-ylphosphonates, anticoagulant activity, dialkyl phosphites, malononitrile, piperazine, salicylaldehyde
derivatives, ultrasound promoted synthesis.
Abstract: Background: One of the alarming difficulties in the field of hematology is the Coagulant
disorders. Despite the availability of clinically proven existing anticoagulants, their limitations have
prompted a continuous search for novel anticoagulants.
Objective: The primary objective of the study is to synthesize a series of 2-amino-4H-chromen-4-
ylphosphonate derivatives and to test their anticoagulant activity depending on PT measurements considering
commercial heparin as positive control.
Method: 2-Amino-4H-chromen-4-ylphosphonates were synthesized by the reaction of salicylaldehyde
derivatives (1), malononitrile (2) and dialkyl phosphite (3) in ethanol using piperazine as a catalyst by
ultra-sonication at room temperature. All the title compounds (4a-l) were tested for anticoagulant activity.
Results: The results of the anticoagulant activity of the title compounds revealed that 4j, 4h and 4g
showed prolonged prothrombin time 87.28, 81.81 and 78.42 sec when compared with that of the standard
heparin which has prothrombin time of 121.50 sec.
Conclusion: The findings from this study highlight that ultrasonication of the one pot three component
reaction of salicylaldehyde derivatives, malononitrile and dialkyl phosphite with piperazine as a catalyst
for the synthesis of 2-amino-4H-chromen-4-ylphosphonates is the best method. In vitro coagulant assay
in terms of prothrombin time (PT) revealed that 4j, 4h and 4g possess promising anticoagulant properties.
Other compounds (4a-l) were also found to have significant anticoagulant effect when compared
with the heparin as positive control. Thus, these compounds qualify for further clinical studies to be
used as the blood anticoagulants.
